Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features

Saudi Journal of Biological Sciences

Volumn 25, Issue 3, 2018, Pages 586-596

  Almasaudi, Saad B ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Acinetobacter; Characteristics; Epidemiology; Multi drug resistance; Nosocomial infections

Indexed keywords

EID: 84975782114     PISSN: 1319562X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjbs.2016.02.009     Document Type: Review

References (61)

1. Abbo, A., Navon-Venezia, S., Hammer-Muntz, O., Krichali, T., Siegman-Igra, Y., Carmeli, Y., Multidrug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 11 (2005), 22–29.
2. Balachandran, C., Duraipandiyan, V., Emi, N., Ignacimuthu, S., Antimicrobial and cytotoxic properties of Streptomyces sp. (ERINLG-51) isolated from Southern Western Ghats. South Indian J. Biol. Sci. 1 (2015), 7–14.
3. Basri, R., Zueter, A.R., Mohamed, Z., Alam, M.K., Norsa'adah, B., Hasan, S.A., Hasan, H., Ahmad, F., Burden of bacterial meningitis: a retrospective review on laboratory parameters and factors associated with death in meningitis, Kelantan Malaysia. Nagoya J. Med. Sci., 77, 2015, 59.
4. Beggs, C., Kerr, K., Snelling, A., Sleigh, P., Acinetobacter spp. and the clinical environment. Indoor Built Environ. 15 (2006), 19–24.
5. Bergogne-Berezin, E., Towner, K., Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev., 9, 1996, 148.
6. Bonomo, R.A., Szabo, D., Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43 (2006), S49–S56.
7. Brisou, J., Classification of Pseudomonadaceae. Ann. Inst. Pasteur. 93 (1957), 397–404.
8. Brisou, J., Prevot, A., Studies on bacterial taxonomy. X. The revision of species under Acromobacter group. Ann. Inst. Pasteur. 86 (1954), 722–728.
9. Cisneros, J., Rodriguez-Bano, J., Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin. Microbiol. Infect. 8 (2002), 687–693.
10. Dijkshoorn, L., The diversity of the genus Acinetobacter. Gerischer, U., (eds.) Acinetobacter Molecular Biology, 2008, Caister Academic Press ISBN.
11. Dinc, G., Demiraslan, H., Elmali, F., Ahmed, S.S., Alp, E., Doganay, M., Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. N. Microbiol. 38 (2015), 67–73.
12. Doi, Y., Arakawa, Y., 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45 (2007), 88–94.
13. Doughari, H.J., Ndakidemi, P.A., Human, I.S., Benade, S., The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ. 26 (2011), 101–112.
14. Ebringer, A., An ante-mortem test for bovine spongiform encephalopathy involving “myelin-acinetobacter-neurofilaments” (MAN) tested in 12 strains of Acinetobacter bacteria. Multiple Sclerosis, Mad Cow Disease and Acinetobacter, 2015, Springer, 67–78.
15. Eliopoulos, G.M., Maragakis, L.L., Perl, T.M., Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46 (2008), 1254–1263.
16. Erridge, C., Moncayo-Nieto, O.L., Morgan, R., Young, M., Poxton, I.R., Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J. Med. Microbiol. 56 (2007), 165–171.
17. Falagas, M.E., Vardakas, K.Z., Kapaskelis, A., Triarides, N.A., Roussos, N.S., Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int. J. Antimicrob. Agents, 2015.
18. Fournier, P.E., Richet, H., Weinstein, R.A., The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 42 (2006), 692–699.
19. Gallagher, L.A., Ramage, E., Weiss, E.J., Radey, M., Hayden, H.S., Held, K.G., Huse, H.K., Zurawski, D.V., Brittnacher, M.J., Manoil, C., Resources for genetic and genomic analysis of emerging pathogen Acinetobacter baumannii. J. Bacteriol., 2015 00131–00115.
20. Garnacho-Montero, J., Amaya-Villar, R., Ferrándiz-Millón, C., Díaz-Martín, A., López-Sánchez, J.M., Gutiérrez-Pizarraya, A., Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia. Expert Rev. Anti Infect. Ther., 2015, 1–9.
21. Gerner-Smidt, P., The epidemiology of Acinetobacter calcoaceticus: biotype and resistance-pattern of 328 strains consecutively isolated from clinical specimens. Acta Pathol. Microbiol. Scand. Ser. B 95 (1987), 5–11.
22. OXA-23. J. Antimicrob. Chemother. 70 (2015), 1016–1020.
23. Guide, A.A., 2010. Guide to the Elimination of multidrug-resistant Acinetobacter baumannii transmission in healthcare settings. 36th Annual APIC Educational Conference and International Meeting Proceedings, Fort Lauderdale, FL. 2009 Jun 10.
24. Houang, E.T., Chu, Y., Leung, C., Chu, K., Berlau, J., Ng, K., Cheng, A., Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J. Clin. Microbiol. 39 (2001), 228–234.
25. Islahi, S., Ahmad, F., Khare, V., Yaqoob, S., Shukla, P., Singh, Y., Incidence and risk factors associated with Acinetobacter species infection in hospitalised patients in a tertiary care hospital in North-India. J. Commun. Dis. 46 (2015), 10–12.
26. Jain, R., Danziger, L.H., Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. 38 (2004), 1449–1459.
27. Jung, J., Park, W., Acinetobacter species as model microorganisms in environmental microbiology: current state and perspectives. Appl. Microbiol. Biotechnol. 99 (2015), 2533–2548.
28. Juni, E., Janik, A., Transformation of Acinetobacter calcoaceticus (Bacterium anitratum). J. Bacteriol. 98 (1969), 281–288.
29. Kamolvit, W., Sidjabat, H.E., Paterson, D.L., Molecular epidemiology and mechanisms of carbapenem resistance of Acinetobacter spp. in Asia and Oceania. Microb. Drug Resist. 21 (2015), 424–434.
30. Kanafani, A.Z., Kanj, S.S., 2014. Ministry of Health, Kingdome of Saudi Arabia. < http://www.uptodate.com/contents/acinetobacter-infection-treatment-and-prevention>.
31. Karageorgopoulos, D.E., Falagas, M.E., Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8 (2008), 751–762.
32. Kurcik-Trajkovska, B., Acinetobacter spp. – a serious enemy threatening hospitals worldwide. Maced. J. Med. Sci. 2 (2009), 157–162.
33. Lambert, T., Gerbaud, G., Galimand, M., Courvalin, P., Characterization of Acinetobacter haemolyticus aac (6′)-Ig gene encoding an aminoglycoside 6′-N-acetyltransferase which modifies amikacin. Antimicrob. Agents Chemother. 37 (1993), 2093–2100.
34. Lee, K., Yong, D., Jeong, S.H., Chong, Y., Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med. J. 52 (2011), 879–891.
35. Luna, C.M., Aruj, P.K., Nosocomial acinetobacter pneumonia. Respirology 12 (2007), 787–791.
36. Manchanda, V., Sanchaita, S., Singh, N., Multidrug resistant acinetobacter. J. Global Infect. Dis., 2, 2010, 291.
37. Mugnier, P., Poirel, L., Pitout, M., Nordmann, P., Carbapenem-resistant and OXA-23-producing Acinetobacter baumannii isolates in the United Arab Emirates. Clin. Microbiol. Infect. 14 (2008), 879–882.
38. Mugnier, P.D., Bindayna, K.M., Poirel, L., Nordmann, P., Diversity of plasmid-mediated carbapenem-hydrolysing oxacillinases among carbapenem-resistant Acinetobacter baumannii isolates from Kingdom of Bahrain. J. Antimicrob. Chemother. 63 (2009), 1071–1073.
39. Munoz-Price, L.S., Weinstein, R.A., Acinetobacter infection. N. Engl. J. Med. 358 (2008), 1271–1281.
40. Nowak, J., Seifert, H., Higgins, P.G., Prevalence of eight RND-efflux pump genes in epidemiologically characterised Acinetobacter baumannii of worldwide origin. J. Med. Microbiol., 2015, 000069.
41. Peleg, A.Y., Seifert, H., Paterson, D.L., Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21 (2008), 538–582.
42. Perez, F., Hujer, A.M., Hujer, K.M., Decker, B.K., Rather, P.N., Bonomo, R.A., Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51 (2007), 3471–3484.
43. Pogue, J.M., Cohen, D.A., Marchaim, D., Polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin. Infect. Dis. 60 (2015), 1304–1307 civ044.
44. Potron, A., Poirel, L., Nordmann, P., Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int. J. Antimicrob. Agents 45 (2015), 568–585.
45. Saeed, N.K., Kambal, A.M., El-Khizzi, N.A., Antimicrobial-resistant bacteria in a general intensive care unit in Saudi Arabia. Saudi Med. J. 31 (2010), 1341–1349.
46. Seifert, H., Dijkshoorn, L., Gerner-Smidt, P., Pelzer, N., Tjernberg, I., Vaneechoutte, M., Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J. Clin. Microbiol. 35 (1997), 2819–2825.
47. Sherertz, R.J., Sullivan, M.L., An outbreak of infections with Acinetobacter calcoaceticus in burn patients: contamination of patients’ mattresses. J. Infect. Dis. 151 (1985), 252–258.
48. Smith, M.G., Gianoulis, T.A., Pukatzki, S., Mekalanos, J.J., Ornston, L.N., Gerstein, M., Snyder, M., New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes Dev. 21 (2007), 601–614.
49. Tomaras, A.P., Dorsey, C.W., Mcqueary, C., Actis, L.A., 2008. Molecular basis of Acinetobacter virulence and pathogenicity. In: Acinetobacter Molecular Microbiology.
50. Towner, A., The genus Acinetobacter. The Prokaryotes, 2006, Springer, 746–758.
51. Towner, A., Park, A.N., Gander, R., Orr, K., Arocha, D., Zhang, S., Greenberg, D.E., Acinetobacter infections and outcomes at an academic medical center: a disease of long-term care. Open Forum Infectious Diseases, 2015, Oxford University Press ofv023.
52. Urban, C., Segal-Maurer, S., Rahal, J.J., Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin. Infect. Dis. 36 (2003), 1268–1274.
53. Utnes, A.L., Sørum, V., Hülter, N., Primicerio, R., Hegstad, J., Kloos, J., Nielsen, K.M., Johnsen, P.J., Growth phase-specific evolutionary benefits of natural transformation in Acinetobacter baylyi. ISME J., 2015.
54. Vashist, J., Tiwari, V., Das, R., Kapil, A., Rajeswari, M.R., Analysis of penicillin-binding proteins (PBPs) in carbapenem resistant Acinetobacter baumannii. Indian J. Med. Res., 133, 2011, 332.
55. Villegas, M.V., Hartstein, A.I., Acinetobacter outbreaks, 1977–2000. Infect. Control 24 (2003), 284–295.
56. Vourli, S., Frantzeskaki, F., Meletiadis, J., Stournara, L., Armaganidis, A., Zerva, L., Dimopoulos, G., Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. Int. J. Antimicrob. Agents, 2015.
57. Weernink, A., Severin, W., Tjernberg, I., Dijkshoorn, L., Pillows, an unexpected source of Acinetobacter. J. Hosp. Infect. 29 (1995), 189–199.
58. Whitman, T.J., Qasba, S.S., Timpone, J.G., Babel, B.S., Kasper, M.R., English, J.F., Sanders, J.W., Hujer, K.M., Hujer, A.M., Endimiani, A., Occupational transmission of Acinetobacter baumannii from a United States serviceman wounded in Iraq to a health care worker. Clin. Infect. Dis. 47 (2008), 439–443.
59. Yadav, R., Landersdorfer, C.B., Nation, R.L., Boyce, J.D., Bulitta, J.B., Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 59 (2015), 2286–2298.
60. Yang, H., Hu, L., Liu, Y., Ye, Y., Li, J., Detection of the plasmid-mediated quinolone resistance determinants in clinical isolates of Acinetobacter baumannii in China. J. Chemother., 2015 1973947815Y.0000000017.
61. Zowawi, H.M., Sartor, A.L., Sidjabat, H.E., Balkhy, H.H., Walsh, T.R., Al Johani, S.M., Aljindan, R.Y., Alfaresi, M., Ibrahim, E., Al-Jardani, A., Molecular epidemiology of carbapenem resistant Acinetobacter baumannii in the Gulf Cooperation Council States. Dominance of OXA-23-type producers. J. Clin. Microbiol., 2015 02784–02714.